IDH2 and central nervous system cancer: CMRO2 was decreased (p = 0.037) in low-grade glioma with a mutated IDH gene, and MTI was significantly increased in glioma grade III with IDH mutation (p = 0.013) when compared with the IDH-wildtype counterparts.